Skip header and navigation

Refine By

1145 records – page 1 of 115.

A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults.

https://arctichealth.org/en/permalink/ahliterature56626
Source
Scand J Infect Dis. 2002;34(8):610-4
Publication Type
Article
Date
2002
Author
K. Levie
I. Gjorup
P. Skinhøj
M. Stoffel
Source
Scand J Infect Dis. 2002;34(8):610-4
Date
2002
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Belgium
Comparative Study
Denmark
Dose-Response Relationship, Drug
Female
Hepatitis B - prevention & control
Hepatitis B Antibodies - analysis
Hepatitis B Surface Antigens - analysis
Hepatitis B vaccines - administration & dosage
Humans
Immunity - physiology
Immunization - methods
Immunization Schedule
Male
Reference Values
Research Support, Non-U.S. Gov't
Sensitivity and specificity
Single-Blind Method
Vaccines, Synthetic - administration & dosage
Abstract
An open-label randomized study was undertaken to compare a 2-dose regimen (Months 0 and 6) of hepatitis B surface antigen (HBsAg) vaccine formulated with a novel adjuvant (HBsAg/AS04) with a standard 3-dose regimen (Months 0, 1 and 6) of licensed recombinant HBsAg vaccine in terms of immunogenicity and reactogenicity when administered to healthy subjects aged between 15 and 40 y. At 1 and 6 months after the full vaccination course there was a 100% seroprotection rate (anti-HBs > or = 10 mIU/ml) with the HBsAg/AS04 vaccine, compared with a 99% response rate with the licensed vaccine. The corresponding geometric mean titres were significantly higher for the novel vaccine compared to the standard vaccine: 15,468 and 2,745 mIU/ml at Months 7 and 12 vs. 6,274 and 1,883 mIU/ml, respectively. There was a higher prevalence of local symptoms with the adjuvant vaccine (90% of doses) than with the standard vaccine (48% of doses). However, these symptoms (pain, swelling and redness) were predominantly of mild-to-moderate intensity and resolved rapidly without treatment. A 2-dose regimen of the new HBsAg/AS04 adjuvant vaccine therefore compared favourably to the standard regimen in healthy young adults. It is anticipated that the simplified vaccination schedule may improve compliance and reduce costs.
PubMed ID
12238579 View in PubMed
Less detail

A 25-year follow-up study of drug addicts hospitalised for acute hepatitis: present and past morbidity.

https://arctichealth.org/en/permalink/ahliterature7324
Source
Eur Addict Res. 2003 Apr;9(2):80-6
Publication Type
Article
Date
Apr-2003
Author
Susanne Rogne Gjeruldsen
Bjørn Myrvang
Stein Opjordsmoen
Author Affiliation
Department of Infectious Diseases, Ullevål University Hospital, Oslo, Norway. s.m.r.gieruldsen@iwoks.uio.no
Source
Eur Addict Res. 2003 Apr;9(2):80-6
Date
Apr-2003
Language
English
Publication Type
Article
Keywords
Acute Disease
Adult
Alcoholism - diagnosis - epidemiology
Comorbidity
Cross-Sectional Studies
Female
Follow-Up Studies
HIV Seropositivity - diagnosis - epidemiology
Health Behavior
Hepatitis B - epidemiology - rehabilitation
Hepatitis C - epidemiology - rehabilitation
Hospitalization - statistics & numerical data
Humans
Life Style
Male
Mental Disorders - diagnosis - epidemiology
Middle Aged
Norway
Rehabilitation, Vocational - statistics & numerical data
Skin Diseases, Infectious - diagnosis - epidemiology
Social Environment
Substance Abuse, Intravenous - epidemiology - rehabilitation
Treatment Outcome
Abstract
The aim of the study was to investigate present and past morbidity in drug addicts, 25 years after hospitalisation for acute hepatitis B or hepatitis nonA-nonB. The hospital records for 214 consecutively admitted patients were analysed, and a follow-up study on 66 of the 144 patients still alive was performed. At follow-up, 1 of 54 (1.8%) hepatitis B patients was still HBsAg positive. Twelve patients originally diagnosed as hepatitis nonA-nonB were all among 54 found to be anti-hepatitis C virus (anti-HCV) positive, and the total anti-HCV prevalence was 81.8%. Twelve (22.2%) of the HCV cases were unknown before the follow-up examination. Four (6.1%) participants were anti-human immunodeficiency virus positive, only 1 was on antiretroviral therapy, and none had developed AIDS. Other chronic somatic diseases were a minor problem, whereas drug users reported skin infections as a frequent complication. Forty-three patients (65%) had abandoned addictive drugs since the hospital stay. Serious mental disorders were reported by 19 patients (28.8%), and 17 (25.8%) regarded themselves as present (9) and former (8) compulsive alcohol drinkers. A large proportion of the participants were granted disability pension (39%), a majority because of psychiatric disorders, drug and alcohol abuse.
PubMed ID
12644734 View in PubMed
Less detail

The 1971-72 epidemic of acute viral hepatitis in Godthaab, Greenland.

https://arctichealth.org/en/permalink/ahliterature42467
Source
Scand J Gastroenterol. 1976;11(3):257-62
Publication Type
Article
Date
1976
Author
O. Grove
F. Börsting Larsen
V. Reinicke
Source
Scand J Gastroenterol. 1976;11(3):257-62
Date
1976
Language
English
Publication Type
Article
Keywords
Acute Disease
Adolescent
Adult
Age Factors
Child
Child, Preschool
Epistaxis - etiology
Female
Greenland
Hepatic Encephalopathy - etiology
Hepatitis A - complications - epidemiology - prevention & control
Hepatitis B antigens
Humans
Infant
Male
Middle Aged
gamma-Globulins - therapeutic use
Abstract
Viral hepatitis has been known to occur among the Greenland population endemically as well as in smaller and larger epidemics. A large epidemic of acute hepatitis comprising around 9% of the entire population, viz. more than 4000 notified cases, swept through Greenland between October 1970 and December 1972. 996 verified cases were seen in the Godthaab district and subjected to more detailed studies. Most of the Godthaab cases were seen among children and adolescents, and no disease was observed in children less than one year of age. Out of 996 diagnosed cases 9 showed acute hepatic failure with coma. Two further cases of hepatic coma were referred for treatment from outside the district. Three of these 11 patients recovered spontaneously. Of the residual 8 cases 6 were treated with exchange transfusions and steroids. Four of these survived and recovered completely. No lasting sequelae had been registered in any of the surviving cases of the epidemic up to June 1975 (2 1/2 years after cessation of the epidemic). Prophylaxis with gamma-globulin was undertaken in a medium-sized settlement in which practically the entire population received gamma-globulin when the first case of hepatitis was diagnosed. In this settlement only 7 out of 297 inhabitants contracted hepatitis. By contrast, in a similar settlement where no gamma-globulin was given, more than 30% of the population developed icteric hepatitis. The clinical features and the prophylactic effect of gamma-globulin seem to indicate that the epidemic was caused by the hepatitis A virus. In accordance with this, transitory Australia-antigenaemia was demonstrated in the acute phase in only 2.6% of the cases, possibly inidicating a small admixture of acute hepatitis type B to the epidemic predominantly caused by hepatitis A virus.
PubMed ID
58437 View in PubMed
Less detail

[A case of the combined course of viral hepatitis B and C with mechanical jaundice]

https://arctichealth.org/en/permalink/ahliterature21400
Source
Lik Sprava. 1998 Jul-Aug;(5):146-8
Publication Type
Article

Active cases of hepatitus [sic] B found in NANA Region.

https://arctichealth.org/en/permalink/ahliterature11
Source
Northwest Arctic NUNA. 5:3.
Publication Type
Article
Date
1984
Source
Northwest Arctic NUNA. 5:3.
Date
1984
Language
English
Geographic Location
U.S.
Publication Type
Article
Physical Holding
Alaska Medical Library
Keywords
Selawik
HBV
Hepatitis B
Notes
From: Fortuine, Robert et al. 1993. The Health of the Inuit of North America: A Bibliography from the Earliest Times through 1990. University of Alaska Anchorage. Citation number 1897.
Less detail

1145 records – page 1 of 115.